- ￥164 - 3176
- TargetMol
- T4226
- 2026年07月07日
2 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- CAS号：
841301-32-4
- 规格：
1mLx10mM(inDMSO)/1mg/5mg/10mg/25mg/50mg/100mg
| 规格： | 1mLx10mM(inDMSO) | 产品价格： | ￥351.0 |
|---|---|---|---|
| 规格： | 1mg | 产品价格： | ￥164.0 |
| 规格： | 5mg | 产品价格： | ￥330.0 |
| 规格： | 10mg | 产品价格： | ￥529.0 |
| 规格： | 25mg | 产品价格： | ￥1104.0 |
| 规格： | 50mg | 产品价格： | ￥1904.0 |
| 规格： | 100mg | 产品价格： | ￥3176.0 |
Product Introduction
Bioactivity
| 名称 | Amenamevir |
| 描述 | Amenamevir (ASP2151) is a novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2 (EC50: 14 ng/mL). |
| 细胞实验 | The antiviral activities of Amenamevir and ACV against HSVs are tested using a plaque reduction assay. Briefly, HEF cells are seeded into multi-well plates and incubated until they form a monolayer. After the medium is removed, the cells are infected with HSV-1 or HSV-2, and the plates are further incubated for 1 h at 37°C. The cells are washed twice with maintenance medium and then treated with the test compound (including Amenamevir) until clear plaques appear. The cells are then fixed with 10% formalin in phosphate-buffered saline, stained with a 0.02% crystal violet solution, and the number of plaques is determined under a light microscope. The EC50, which represents the concentration of test compound needed to reduce the plaque number by 50%, is calculated using nonlinear regression analysis with a sigmoid-maximum effect (Emax) model[1]. |
| 动物实验 | Female hairless mice (HOS: HR-1, 7 to 8 weeks old) are infected with a suspension of HSV-1 strain WT51 (15 μL/mouse; titer, 2×108 PFU/mL) or CI-116 (15 μL/mouse; titer, 4×107 PFU/mL) in the dorsolateral skin stripped as a small square using a needle, under anesthesia. The day of HSV-1 infection is designated day zero postinfection. Total daily doses of 1, 3, 10, 30, or 100 mg/kg/day ASP2151 are orally administered to HSV-1-infected mice (n=5) for 5 days. Amenamevir (ASP2151) treatments are started 2 to 3 h after HSV infection either as a single daily dose (every 24 h, q24h) or as two (every 12 h, q12h) or three (every 8 h, q8h) divided doses. Lesion scores and intradermal HSV-1 titers are measured on day 5 postinfection[1]. |
| 体外活性 | Amenamevir对HSV-1和HSV-2的平均EC50分别为14 ng/mL（范围7.7-20）和30 ng/mL（范围15-58），而Acyclovir（ACV）的相应值分别为29 ng/mL（范围18-38）和71 ng/mL（范围45-95）。 |
| 体内活性 | Amenamevir（ASP2151, 3-30 mg/kg/day）以剂量依赖性方式加速病毒滴度的减少，不论给药间隔如何，均可剂量依赖性降低HSV-1滴度和病损评分。根据相关性曲线，Amenamevir（口服）能完全抑制HSV-1的生长，并估算出以下药动学参数：血清中Cmax达到或超过10,000 ng/mL；AUC24h达到或超过60 μg·h/ml；T>100保持时间为21至24小时。感染后第5天，Amenamevir在血浆中的平均浓度随剂量增加而升高，3 mg Amenamevir/g或更高剂量显著降低了皮内HSV-1的滴度。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | 10% DMSO+90% (20% SBE-β-CD in Saline) : 10 mg/mL (20.72 mM), Suspension. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (10.36 mM), Solution. 10% DMSO+90% Saline : < 5 mg/mL (10.36 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 50 mg/mL (103.62 mM), Sonication is recommended. |
| 关键字 | RNASynthesis | RNA Synthesis | Inhibitor | inhibit | HSV | Herpes simplex virus | helicase-primase | DNASynthesis | DNA Synthesis | ASP-2151 | ASP 2151 | Amenamevir |
| 相关产品 | Oxyresveratrol | Carbazole | Hexane-1,6-diol | Guanidine hydrochloride | 1,4-Naphthoquinone | 5-Fluorouracil | Usnic Acid | Adenine hemisulfate | Erythromycin thiocyanate | Adenine | L-Lysine | Thymidine |
| 相关库 | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-Aging Compound Library | Approved Drug Library | Anti-Viral Compound Library | Immunology/Inflammation Compound Library | Drug Repurposing Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Drug Library |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
官网有文献
技术资料暂无技术资料 索取技术资料
文献支持
阿莫奈韦【841301-32-4】
￥164 - 3176
